These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20978380)

  • 1. Update on mucosal HIV vaccine vectors.
    Duerr A
    Curr Opin HIV AIDS; 2010 Sep; 5(5):397-403. PubMed ID: 20978380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonhuman primate models for HIV vaccine development.
    Letvin NL
    Immunodefic Rev; 1992; 3(3):247-60. PubMed ID: 1510838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encouraging vaccine results from primate models of HIV type 1 infection.
    Schultz A
    AIDS Res Hum Retroviruses; 1998 Oct; 14 Suppl 3():S261-3. PubMed ID: 9814953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
    Paris RM; Kim JH; Robb ML; Michael NL
    Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV/AIDS vaccines: a need for new concepts?
    Girard MP; Bansal GP
    Int Rev Immunol; 2008; 27(6):447-71. PubMed ID: 19065351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AIDS vaccine development: the long and winding road.
    Garber DA; Feinberg MB
    AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in mucosal HIV vaccine development: lessons from non-human primate models.
    Tuero I; Robert-Guroff M
    Viruses; 2014 Aug; 6(8):3129-58. PubMed ID: 25196380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge.
    Dumais N; Patrick A; Moss RB; Davis HL; Rosenthal KL
    J Infect Dis; 2002 Oct; 186(8):1098-105. PubMed ID: 12355360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal HIV vaccines: a holy grail or a dud?
    Azizi A; Ghunaim H; Diaz-Mitoma F; Mestecky J
    Vaccine; 2010 May; 28(24):4015-26. PubMed ID: 20412879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.
    Ellenberger D; Otten RA; Li B; Aidoo M; Rodriguez IV; Sariol CA; Martinez M; Monsour M; Wyatt L; Hudgens MG; Kraiselburd E; Moss B; Robinson H; Folks T; Butera S
    Virology; 2006 Aug; 352(1):216-25. PubMed ID: 16725169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of mucosal immunity to HIV-1.
    Jespers V; Harandi AM; Hinkula J; Medaglini D; Le Grand R; Stahl-Hennig C; Bogers W; El Habib R; Wegmann F; Fraser C; Cranage M; Shattock RJ; Spetz AL
    Expert Rev Vaccines; 2010 Apr; 9(4):381-94. PubMed ID: 20370549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.
    Hone DM; DeVico AL; Fouts TR; Onyabe DY; Agwale SM; Wambebe CO; Blattner WA; Gallo RC; Lewis GK
    J Hum Virol; 2002; 5(1):17-23. PubMed ID: 12352264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive value of primate models for AIDS.
    Haigwood NL
    AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and obstacles in the development of an AIDS vaccine.
    Letvin NL
    Nat Rev Immunol; 2006 Dec; 6(12):930-9. PubMed ID: 17124514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An HIV-based lentiviral vector as HIV vaccine candidate: Immunogenic characterization.
    Lemiale F; Asefa B; Ye D; Chen C; Korokhov N; Humeau L
    Vaccine; 2010 Feb; 28(8):1952-61. PubMed ID: 20188251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
    Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
    AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites.
    Mestecky J
    J Reprod Immunol; 2006 Dec; 72(1-2):1-17. PubMed ID: 17095369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.